Adjuvant pembrolizumab significantly improved disease-free survival (DFS) compared to placebo in patients who had undergone complete resection, according to findings from the phase 3 PEARLS study.
VANCOUVER, British Columbia, March 04, 2022 Core One Labs Inc. , is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. , has entered into an agreement with the. | March 4, 2022
04.03.2022 - VANCOUVER, British Columbia, March 04, 2022 (GLOBE NEWSWIRE) - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. . Seite 1